Drugs / PROSTAC-V/TRICOM
last change Nov 2012 re-read 2 minutes ago

PROSTAC-V/TRICOM

Developed for
prostate cancer
Investigated by
National Cancer Institute (NCI)

Trials 1 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00450619 Feb 2007 → Nov 2012 prostate cancer National Cancer Institute (NCI) Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as PROSTAC-V/TRICOM PROSTAC-V/TRICOM (vaccinia) 2 x 10\^8 plaque forming unit (pfu) subcutaneously on day 1.” NCT00450619
Route Subcutaneous “2 x 10\^8 plaque forming unit (pfu) subcutaneously on day 1” NCT00450619